There are currently 542 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Madison, Wisconsin
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
NCT02688959
Recruiting
The investigators will perform a feasibility/pilot trial of two non-pharmacological interventions for ADHD in college students.
Gender:
ALL
Ages:
Between 18 years and 23 years
Trial Updated:
05/29/2025
Locations: University of Wisconsin-Madison, Waisman Center, Madison, Wisconsin
Conditions: Attention Deficit Hyperactivity Disorder
Register for Updates
UW Undiagnosed Genetic Diseases Program
NCT04586075
Recruiting
The primary purpose of this study is to discover new disease genes for rare Mendelian disorders and its secondary purpose include diagnosing people with rare genetic disorders that have not been previously diagnosed through conventional clinical means, learning more about the pathobiology of genetic disorders, and developing novel diagnostic technologies and analytics. 500 participants with undiagnosed and suspected genetic disorders will be recruited.
Gender:
ALL
Ages:
100 years and below
Trial Updated:
05/29/2025
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Rare Diseases, Genetic Disease, Undiagnosed Disease
Register for Updates
Storytelling and Mindfulness for Graduate Student Wellbeing
NCT05826860
Recruiting
The purpose of this study is to evaluate an intervention for improving Science, Technology, Engineering, and Math (STEM) graduate student wellbeing. Participants will be recruited from the University of Wisconsin-Madison graduate student body. Data will be collected from participants for up to 2 years, and the investigators anticipate that the study will last for 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Wisconsin Institute for Discovery, Madison, Wisconsin
Conditions: Depression, Anxiety, Burnout, Student
Register for Updates
Mental Health App for Cancer Survivors Study
NCT06472726
Recruiting
The goal of this clinical trial is to adapt a mental health digital app to treat depression among head and neck cancer patients and survivors. Participants will download and use the digital mental health app for a 6-week period, and will complete related surveys.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/29/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Head and Neck Cancer, Head and Neck Cancers, Depression
Register for Updates
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
NCT05255601
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/28/2025
Locations: UW Health - American Family Children's Hospital Pediatric Bone Marrow Transplant Clinic, Madison, Wisconsin
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
Register for Updates
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333
Recruiting
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Congestive Heart Failure
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608
Recruiting
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Clinical Study Site, Madison, Wisconsin
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
NCT07006675
Recruiting
Two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial evaluating the efficacy of standard pain management without NSAIDs (Group 1) vs. standard pain management plus up to 6 weeks of NSAIDs (Group 2) in the treatment of tibial shaft fractures.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Tibial Fractures, Pain
Register for Updates
Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes Among Socioeconomically Disadvantaged Communities
NCT06763952
Recruiting
This study aims to investigate whether a novel artificial intelligence based screening strategy (AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education or AI-BRIDGE), which allows primary care providers to screen patients for vision-threatening diabetic eye disease in the primary care clinic, improves screening and follow-up care rates across race/ethnicity groups and reduces racial/ethnic disparities in screening.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/23/2025
Locations: UW School of Medicine and Public Health, Madison, Wisconsin
Conditions: Vision, Diabetes
Register for Updates
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
NCT05101551
Recruiting
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study. This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated do... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/22/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Acute Myeloid Leukemia
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates